Hi Sergio,
while the street is digesting the gains from early March, HHGP and Nanotech advanced to new highs. HHGP is now around Net asset value.
And their 2 "core" medical device holdigns in Kriton Medical and Neurometrix are nearing a stage where an IPO could be in shore and with it HHGP would literally unlock a "pot of gold" for all us investors..
Meanwhile I acquired a strep throat and feeling quite subdued. Did research Japan however and found some gems of a lifetime. Imagine major pharma corporations with an ample stuffed pipeline selling for under PSR of 2..
Listed are only those firms where I had a chance to look at their R&D pipelines in English and where I think that valuation is low..
My top pick: Kaken Pharmaceutical - 4521.J - 740 Yen www.kaken.co.jp
Y-70.3bn sales, PSR 1, P/B 2, PE 35 R&D 8%/sales
nice pipeline .. 17 compounds .. 5 approved, 5 NDA, 5 Phase 2, 2 Stage 1, 2 Preclinical, 4 Drug discovery collaborations .. noteworthy their licensing of a top SCIOS product in the past for Japan (& Asia ?). They are famous for in-licensing other products..
Tanabe Seiyaku - 4508.J - 1150 Yen
Y-194bn sales, PSR 1.76, P/B 1.76, PE 17
Pipeline: 18 compounds ... 7 NDA, 3 Phase 2, 7x Trials, 1x launch
Dainippon Pharma - 4506.J - 1350 Yen
Y-159bn sales, PSR 1.44, P/B 2.10, PE 23,
Pipeline: 17 compounds ... 1 launch, 5 NDA, 1 P3, 6 P2, 4 P1
Sankyo - 4501.J - 2000 Yen
Y-545bn sales, PSR 1.68 PE 25 P/B 1.40 R&D 14%/Rev.
Pipeline: 26 compounds .. 5 filed, 2 P3, 6 P2, 10 P1, 5 PreCl
looks like I'm going to buy that Kaken Pharma, think their shares are listed on the PinkSheets in the US also..
rgrds
CROSSY |
